Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

3.920 -0.150 (-3.69%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	296,019
Open	4.040
Bid (Size)	3.940 (300)
Ask (Size)	4.010 (800)
Prev. Close	4.070
Today's Range	3.905 - 4.140
52wk Range	1.110 - 5.500
Shares Outstanding	20,187,904
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease

December 19, 2025

Via Investor Brand Network

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

December 18, 2025

From Annovis Bio Inc.

Via GlobeNewswire

Performance

YTD	+7.4%	+7.4%
1 Month	-12.1%	-12.1%
3 Month	+78.2%	+78.2%
6 Month	+37.5%	+37.5%
1 Year	-24.0%	-24.0%

More News

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session

December 16, 2025

Via Investor Brand Network

Annovis to Host Corporate Update Webinar on January 28, 2026

December 16, 2025

From Annovis Bio Inc.

Via GlobeNewswire

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting

December 03, 2025

Via Investor Brand Network

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

December 03, 2025

From Annovis Bio Inc.

Via GlobeNewswire

Annovis Announces Two Presentations at the CTAD 2025 Conference

November 24, 2025

From Annovis Bio Inc.

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

November 20, 2025

Via Chartmill

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

November 18, 2025

Via Chartmill

Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗

November 18, 2025

Via Stocktwits

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program

November 18, 2025

Via Investor Brand Network

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

Via FinancialNewsMedia

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

From MarketNewsUpdates.com

Via GlobeNewswire

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

November 18, 2025

From Annovis Bio Inc.

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

November 17, 2025

Via Chartmill

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients ↗

November 17, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

November 17, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 17, 2025

Via Benzinga

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology

November 17, 2025

Via Investor Brand Network

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

November 17, 2025

From Annovis Bio Inc.

Via GlobeNewswire

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion

November 12, 2025

Via Investor Brand Network

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion

November 12, 2025

Via Investor Brand Network

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

November 12, 2025

From Annovis Bio Inc.

Via GlobeNewswire

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial

November 06, 2025

Via Investor Brand Network

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

November 06, 2025

From Annovis Bio Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Annovis Bio, Inc. Common Stock publicly traded?

Yes, Annovis Bio, Inc. Common Stock is publicly traded.

What exchange does Annovis Bio, Inc. Common Stock trade on?

Annovis Bio, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Annovis Bio, Inc. Common Stock?

The ticker symbol for Annovis Bio, Inc. Common Stock is ANVS on the New York Stock Exchange

What is the current price of Annovis Bio, Inc. Common Stock?

The current price of Annovis Bio, Inc. Common Stock is 3.920

When was Annovis Bio, Inc. Common Stock last traded?

The last trade of Annovis Bio, Inc. Common Stock was at 01/08/26 07:00 PM ET

What is the market capitalization of Annovis Bio, Inc. Common Stock?

The market capitalization of Annovis Bio, Inc. Common Stock is 79.14M

How many shares of Annovis Bio, Inc. Common Stock are outstanding?

Annovis Bio, Inc. Common Stock has 79M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.